The Future of
Drug Discovery is Here.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Who We Are
Duis irure dolor reprehenderit
in voluptate velit esse cillum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse.
What We Do
Duis irure dolor reprehenderit
in voluptate velit esse cillum
High-Throughput Screening
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
High-Throughput Screening
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
High-Throughput Screening
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Client Outcomes
Duis irure dolor reprehenderit
in voluptate velit esse cillum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse.
News
Duis irure dolor reprehenderit
in voluptate velit esse cillum
The results of joint research with Luxna Biotec, Inc published in “Nucleic Acid Therapeutics”
Hepatotoxicity Reduction Profiles of Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid and 2′-O,4′-C-Spirocyclopropylene Bridged Nucleic Acid Publication Amide-bridged...
Research Article Co-Authored on Ferroptosis MoA Analysis Published in Communications Biology
Protein covariation networks for elucidating ferroptosis inducer mechanisms and potential synergistic drug targets Publication Mechanism of action...
Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein Degraders
December 26, 2024 - Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; “Axcelead DDP”) announced today...